http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Komoto Tatiana Takahasi,Lee Jaehak,Lertpatipanpong Pattawika,Ryu Junsun,Marins Mozart,Fachin Ana Lúcia,Baek Seung Joon 한국독성학회 2021 Toxicological Research Vol.37 No.4
Despite intensive research efforts in recent decades, cancer remains a leading cause of death worldwide. The chalcone family is a promising group of phytochemicals for therapeutic use against cancer development. Naturally-occurring chalcones, as well as synthetic chalcone analogues, have shown many beneficial biological properties, including anti-inflammatory, antioxidant, and anti-cancer activities. In this report, trans-chalcone (TChal) was found to increase cell death in breast cancer cells, assessed using high content screening. Subsequently, using antibody array analysis, TChal was found to increase heme oxygenase-1 (HO-1) expression in TChal-treated breast cancer cells. Blocking of HO-1 by siRNA in breast cancer cells diminished the effect of TChal on cell growth inhibition. TChal-fed mice also showed less tumor growth compared to vehicle-fed mice. Overall, we found that TChal increases HO-1 expression in breast cancer cells, thereby enhancing anti-tumorigenesis. Our results suggest that HO-1 expression could be a potential new target of TChal for anti-tumorigenesis in breast cancer.
( Shunsuke Komoto ),( Satoshi Motoya ),( Yuji Nishiwaki ),( Toshiyuki Matsui ),( Reiko Kunisaki ),( Katsuyoshi Matsuoka ),( Naoki Yoshimura ),( Takashi Kagaya ),( Makoto Naganuma ),( Nobuyuki Hida ),( 대한장연구학회 2016 Intestinal Research Vol.14 No.2
Background/Aims: Anti-tumor necrosis factor drugs (anti-TNF) and thiopurines are important treatment options in patients with inflammatory bowel disease (IBD), including during pregnancy. However, there are limited data on the benefit/risk profile of anti-TNF and thiopurines during pregnancy in Asia. The aim of this study was to analyze pregnancy outcomes of female Japanese IBD patients treated with anti-TNF and/or thiopurines. Methods: This cross-sectional study assessed pregnancy outcomes in 72 women with IBD. Pregnancy outcomes were compared among 31 pregnancies without exposure to infliximab (IFX), adalimumab (ADA), or thiopurines; 24 pregnancies with exposure to anti-TNF treatment (23 IFX, 1 ADA); 7 pregnancies with exposure to thiopurines alone; and 10 pregnancies with exposure to both IFX and thiopurines. Results: Thirty-five of the 41 pregnancies (85.3%) that were exposed to anti-TNF treatment and/or thiopurines resulted in live births after a median gestational period of 38 weeks. Of the 35 live births, 3 involved premature deliveries; 7, low birth weight; and 1, a congenital abnormality. There were 6 spontaneous abortions in pregnancies that were exposed to anti-TNF treatment (17.7%). Pregnancy outcomes among the 4 groups were similar, except for the rate of spontaneous abortions (P =0.037). Conclusions: Exposure to anti-TNF treatment or thiopurines during pregnancy was not related to a higher incidence of adverse pregnancy outcomes in Japanese IBD patients except for spontaneous abortion. (Intest Res 2016;14:139-145)
Life-cycle analyses of very-large scale PV systems using six types of PV modules
Masakazu Ito,Keiichi Komoto,Kosuke Kurokawa 한국물리학회 2010 Current Applied Physics Vol.10 No.2
The authors have been studied the life-cycle analysis of the VLS-PV systems installed in desert area using sc-Si, mc-Si, a-Si/sc-Si, a-Si/lc-Si, CdTe, and CIS PV modules. The sc-Si and a-Si/sc-Si, a-Si/lc-Si are new items from the last studies [1]. It is assumed 1 GW system in Gobi desert including transmission lines. We estimated energy requirement, energy pay-back time, CO2 emissions, and CO2 emissions rate. Concerning the energy requirement, the CIS is the smallest, and biggest energy requirement is the sc-Si. The mc-Si, a-Si/sc-Si, thin-film Si and CdTe are average. The energy pay-back time of the CIS’s VLS-PV system is approximately 1.8 years, and sc-Si is 2.5 years. The others are approximately 2.0–2.3 years. Characteristics of the CO2 emissions rate are almost same as energy pay-back time. The CO2 emissions rate is 43–54 g-CO2/kW h. The mc-Si, a-Si/sc-Si, and CIS shows lower CO2 emissions rate.
Prediction of Bending Fatigue Life of Cracked Out-of-Plane Gusset Joint Repaired by CFRP Plates
Risa Matsumoto,Takafumi Komoto,Toshiyuki Ishikawa,Atsushi Hattori,Hirotaka Kawano 한국강구조학회 2018 International Journal of Steel Structures Vol.18 No.4
Carbon fi ber reinforced polymer (CFRP), plates bonding repair method is one of the simple repair methods for cracked steel structures. In this study, the infl uence of width of CFRP plates on bending fatigue life of out-of-plane gusset joint strengthened with CFRP plates was investigated from the experimental and numerical point of view. In the bending fatigue test of cracked out-of-plane gusset joint strengthened with CFRP plates, the eff ect of width of CFRP plates on crack growth life was clarifi ed experimentally. Namely, it was revealed that the crack growth life becomes larger with increasing the width of CFRP plates. In the numerical approach, the stress intensity factor ( SIF ) at the surface point of a semi-elliptical surface crack was estimated based on the linear fracture mechanics. Furthermore, the extended fatigue life of cracked out-of-plane gusset joint strengthened with CFRP plates was evaluated by using the estimated SIF at the surface point and the empirical formula of the aspect ratio of semi-elliptical crack. As the results of numerical analysis, the estimated fatigue life of the specimen strengthened with CFRP plates showed the good agreement with the test results.
( Fumitaka Suzuki ),( Naoya Hatanaka ),( Etsuya Bando ),( Akira Komoto ) 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Daclatasvir (DCV) combined with asunaprevir (ASV) was the first all-oral treatment to be approved in Japan for chronic hepatitis C virus (HCV) serogroup 1 infection in patients with/without compensated cirrhosis. We report interim findings of a post-marketing survey of DCV+ASV in Japanese patients treated in the routine clinical setting. Methods: The survey aimed to register a total of 3000 HCV-infected patients, including 1000 patients with compensated cirrhosis, between September 2014 and August 2015. All patients received oral DCV 60mg once daily + ASV 100 mg twice daily for 24 weeks. This report includes safety data collected up to 3 July 2016. Results: Of the 3089 patients registered, 2165 (70.0%) patients (female, n=1233 [57.0%]; mean age, 69.1 years [range: 21-92]; compensated cirrhosis, n=862 [39.8%]) are included in the safety set; 1874 (86.6%) patients have completed the treatment period. The main reasons for discontinuation in the safety set were adverse events (n=146 [6.7%]) and lack of efficacy (n=86 [4.0%]). A total of 538 patients (24.85%) in the safety set experienced a total of 811 adverse drug reactions (ADRs). Events corresponding to the composite ADR term ‘hepatic function disorder’ occurred in 315 patients (14.55%). Common ADRs were: hepatic function abnormal (n=133 [6.14%]), increased eosinophil count (n=67 [3.09%]), increased alanine aminotransferase (n=63 [2.91%]), increased aspartate aminotransferase (n=61 [2.82%]), liver disorder (n=58 [2.68%]) and pyrexia (n=53 [2.45%]); rates of ADRs in patients with/without compensated cirrhosis were generally comparable (Table). Serious ADRs which occurred in two or more patients were liver disorder (n=5 [0.23%]), pyrexia (n=4 [0.18%]); hepatic function abnormal (n=3 [0.14%]) hepatic hepatic encephalopathy (n=2 [0.09%]) and jaundice (n=2 [0.09%]); all serious ADRs have/are resolved/resolving and all patients have/are recovered/recovering. No deaths have been reported. Conclusions: DCV + ASV was generally well tolerated in this interim analysis of real-world data.
Complications of Posterior Fusion for Atlantoaxial Instability in Children With Down Syndrome
Yoshiki Takeoka,Kenichiro Kakutani,Hiroshi Miyamoto,Teppei Suzuki,Takashi Yurube,Izumi Komoto,Masao Ryu,Shinichi Satsuma,Koki Uno 대한척추신경외과학회 2021 Neurospine Vol.18 No.4
Objective: To clarify the complications of posterior fusion for atlantoaxial instability (AAI) in children with Down syndrome and to discuss the significance of surgical intervention. Methods: Twenty pediatric patients with Down syndrome underwent posterior fusion for AAI between February 2000 and September 2018 (age, 6.1±1.9 years). C1–2 or C1–3 fusion and occipitocervical fusion were performed in 14 and 6 patients, respectively. The past medical history, operation time, estimated blood loss (EBL), duration of Halo vest immobilization, postoperative follow-up period, and intra- and perioperative complications were examined. Results: The operation time was 257.9±55.6 minutes, and the EBL was 101.6±77.9 mL. Complications related to the operation occurred in 6 patients (30.0%). They included 1 major complication (5.0%): hydrocephalus at 3 months postoperatively, possibly related to an intraoperative dural tear. Other surgery-related complications included 3 cases of superficial infections, 1 case of bone graft donor site deep infection, 1 case of C2 pedicle fracture, 1 case of Halo ring dislocation, 1 case of pseudoarthrosis that required revision surgery, and 1 case of temporary neurological deficit after Halo removal at 2 months postoperatively. Complications unrelated to the operation included 2 cases of respiratory infections and 1 case of implant loosening due to a fall at 9 months postoperatively. Conclusion: The complication rate of upper cervical fusion in patients with Down syndrome remained high; however, major complications decreased substantially. Improved intra- and perioperative management facilitates successful surgical intervention for upper cervical instability in pediatric patients with Down syndrome.